Tenax Therapeutics Amends Global Rights Deal with Orion
Company Announcements

Tenax Therapeutics Amends Global Rights Deal with Orion

Tenax Therapeutics (TENX) has released an update.

Tenax Therapeutics has expanded its partnership with Orion Corporation, amending their agreement to now include worldwide rights to develop and sell levosimendan-based products, excluding treatments for neurological conditions. The revision also adjusts financial terms, decreasing the royalties tied to global sales, while increasing milestone payments for FDA and Japanese regulatory approvals, and altering the commercial milestone payments. Additionally, it lowers the cost per capsule for Tenax, enhancing the company’s position in the market for these products.

For further insights into TENX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskTenax Therapeutics Expands Stock Incentive Plan
TheFlyTenax Therapeutics initiated with an Outperform at Leerink
TheFlyTenax Therapeutics initiated with a Buy at Guggenheim
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App